Jeremy Veenstra-VanderWeele uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism.
Jeremy Veenstra-VanderWeele
From this contributor
Why serotonin medications may yet help children with autism
A class of medications used to treat obsessive-compulsive disorder seems to ease compulsive behaviors in adults with autism. Why can't we tell if these medications work similarly in children with the condition?
Why serotonin medications may yet help children with autism
By
Jeremy Veenstra-VanderWeele
28 January 2020 | 5 min read
How to evaluate new medications for autism
There are no available medications for treating autism’s core symptoms, but there are several candidates in clinical trials. Jeremy Veenstra-VanderWeele describes the factors researchers must take into account when developing drugs for the disorder.
How to evaluate new medications for autism
By
Jeremy Veenstra-VanderWeele
10 June 2014 | 8 min read
Explore more from The Transmitter
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
By
Ashley Juavinett
30 March 2026 | 8 min read
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
By
Dalmeet Singh Chawla
27 March 2026 | 5 min read
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
By
Claudia López Lloreda
26 March 2026 | 4 min read